CHMP approves Xarelto for treatment of PE and secondary prevention of VTE: http://www.press.bayer.com/baynews/baynews.nsf/id/Bayers-Xarelto-Rivaroxaban-Recommended-EU-Approval-Treatment-Pulmonary-Embolism-PE-Prevention?OpenDocument&sessionID=1350667966 The PDUFA date for this indication is on or about 11/2/12; JNJ is Bayer's partner in the US market.